Co-Diagnostics Highlights Ebola Testing and Outbreak Innovation

Salt Lake City, Utah, U.S., September 21, 2026

Co-Diagnostics Focuses on Ebola Diagnostic Innovation

The roundtable follows Co-Diagnostics’ ongoing work to advance molecular diagnostic solutions for Ebola and other emerging infectious diseases. The company said its activities are particularly relevant to the current outbreak involving the Bundibugyo virus, an Ebola virus species responsible for outbreaks that require specialized surveillance and diagnostic capabilities. Co-Diagnostics’ joint venture, CoSara Diagnostics Pvt. Ltd., has advanced development of Bundibugyo virus and pan-Ebola molecular tests intended for centralized laboratories. CoSara has also responded to a request from India’s Centre for Cellular and Molecular Platforms (C-CAMP) for third-party evaluation of its Bundibugyo test. These efforts highlight the importance of accurate molecular detection in supporting outbreak surveillance, laboratory confirmation and public-health decision-making. The company’s diagnostic development is taking place alongside broader efforts to improve access to testing during infectious-disease emergencies. Co-Diagnostics previously announced a collaboration with ReadyGo Diagnostics Ltd. to evaluate whether ReadyGo’s GoCollect® sample-preparation technology could be combined with the company’s Co-Dx PCR platform for blood-based molecular testing at the point of need. The initial focus is decentralized Ebola detection and outbreak response, with the collaboration building on earlier proof-of-concept work involving plasma samples. The companies are evaluating whether the technologies can operate as a streamlined workflow capable of preparing samples and detecting viral infection closer to where testing is required.

Global Partnerships Could Strengthen Outbreak Preparedness

Co-Diagnostics’ participation in the New York roundtable places diagnostic technology, public-health partnerships and outbreak preparedness at the center of discussions involving government and global-health stakeholders. The company said the event will include officials from the U.S. Department of State’s Bureau of Global Health Security and Diplomacy, as well as leaders from the global health research and development community. The broader objective is to examine how scientific innovation and partnerships can help health systems respond more rapidly when emerging infectious diseases are detected. The announcement also illustrates the growing importance of decentralized molecular testing in outbreak response. Conventional diagnostic pathways may depend on centralized laboratory infrastructure, transportation and specialized facilities. Technologies capable of supporting testing closer to the point of need could potentially help shorten diagnostic workflows and provide health authorities with information more rapidly. However, Co-Diagnostics emphasized that its Co-Dx PCR platform and associated tests remain subject to regulatory review and are not currently authorized or available for sale in the United States. Therefore, the Ebola-related technologies described in the announcement should be regarded as development-stage diagnostic solutions, rather than commercially available Ebola tests.

Co-Diagnostics’ involvement in the global health roundtable reflects the company’s broader focus on molecular diagnostics, outbreak preparedness and emerging infectious-disease detection. Its work on Bundibugyo and pan-Ebola testing, together with the evaluation of point-of-need sample preparation, demonstrates an effort to develop diagnostic approaches that could support future responses to viral outbreaks. As Ebola and other emerging pathogens continue to challenge global health systems, rapid, accurate and accessible molecular diagnostics remain an important component of preparedness and response strategies.

Source: Co-Diagnostics press release